ALX Oncology Holdings Inc
NASDAQ:ALXO

Watchlist Manager
ALX Oncology Holdings Inc Logo
ALX Oncology Holdings Inc
NASDAQ:ALXO
Watchlist
Price: 1.42 USD 3.65% Market Closed
Market Cap: 77m USD

ALX Oncology Holdings Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ALX Oncology Holdings Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
ALX Oncology Holdings Inc
NASDAQ:ALXO
Research & Development
-$82.9m
CAGR 3-Years
4%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

ALX Oncology Holdings Inc
Glance View

Market Cap
76.1m USD
Industry
Biotechnology

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. The company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).

ALXO Intrinsic Value
1.1 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is ALX Oncology Holdings Inc's Research & Development?
Research & Development
-82.9m USD

Based on the financial report for Sep 30, 2025, ALX Oncology Holdings Inc's Research & Development amounts to -82.9m USD.

What is ALX Oncology Holdings Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-29%

Over the last year, the Research & Development growth was 38%. The average annual Research & Development growth rates for ALX Oncology Holdings Inc have been 4% over the past three years , -29% over the past five years .

Back to Top